Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 2Radiotherapy 2Etoposide 2Carboplatin 2sintilimab 1irinotecan sucrosofate 1durvalumab 1atezolizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Cancer Extensive Stage × amrubicin × Clear all
NCT03253068 2020-05-19

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Wakayama Medical University

Phase 2 Unknown
25 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡